Paul Little
2021 - Tokai Pharmaceuticals
In 2021, Paul Little earned a total compensation of $2.2M as Chief Financial Officer at Tokai Pharmaceuticals.
Compensation breakdown
| Option Awards | $1,851,199 |
|---|---|
| Salary | $323,269 |
| Other | $1,290 |
| Total | $2,175,758 |
Little received $1.9M in option awards, accounting for 85% of the total pay in 2021.
Little also received $323.3K in salary and $1.3K in other compensation.
Rankings
In 2021, Paul Little's compensation ranked 5,735th out of 12,405 executives tracked by ExecPay. In other words, Little earned more than 53.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,735 out of 12,405 | 54th |
Division Manufacturing | 2,430 out of 5,494 | 56th |
Major group Chemicals And Allied Products | 1,052 out of 2,369 | 56th |
Industry group Drugs | 939 out of 2,090 | 55th |
Industry Pharmaceutical Preparations | 676 out of 1,537 | 56th |
Source: SEC filing on April 28, 2022.
Little's colleagues
We found two more compensation records of executives who worked with Paul Little at Tokai Pharmaceuticals in 2021.